These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 16946130)

  • 1. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
    Harder C; Lau P; Meng A; Whitman SC; McPherson R
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):858-64. PubMed ID: 17272756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.
    de Vries-van der Weij J; Zadelaar S; Toet K; Havekes LM; Kooistra T; Rensen PC
    Atherosclerosis; 2009 Sep; 206(1):153-8. PubMed ID: 19345354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
    Marotti KR; Castle CK; Boyle TP; Lin AH; Murray RW; Melchior GW
    Nature; 1993 Jul; 364(6432):73-5. PubMed ID: 8316302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.
    Van Eck M; Ye D; Hildebrand RB; Kar Kruijt J; de Haan W; Hoekstra M; Rensen PC; Ehnholm C; Jauhiainen M; Van Berkel TJ
    Circ Res; 2007 Mar; 100(5):678-85. PubMed ID: 17293475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CETP on the plasma lipoprotein profile in four strains of transgenic mouse.
    Takahashi H; Takahashi A; Maki M; Sasai H; Kamada M
    Biochem Biophys Res Commun; 2001 Apr; 283(1):118-23. PubMed ID: 11322777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.
    Trion A; de Maat MP; Jukema JW; van der Laarse A; Maas MC; Offerman EH; Havekes LM; Szalai AJ; Princen HM; Emeis JJ
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1635-40. PubMed ID: 15920036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients.
    De Vries R; Beusekamp BJ; Kerstens MN; Groen AK; Van Tol A; Dullaart RP
    Scand J Clin Lab Invest; 2005; 65(8):729-37. PubMed ID: 16319046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.
    Gautier T; Masson D; Jong MC; Pais de Barros JP; Duverneuil L; Le Guern N; Deckert V; Dumont L; Bataille A; Zak Z; Jiang XC; Havekes LM; Lagrost L
    Biochem J; 2005 Jan; 385(Pt 1):189-95. PubMed ID: 15339254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptozotocin-induced increase in cholesterol ester transfer protein (CETP) and its reversal by insulin in transgenic mice expressing human CETP.
    Cheema SK; Rashid-Kolvear F
    Can J Physiol Pharmacol; 2003 Oct; 81(10):997-1004. PubMed ID: 14608418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
    de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.